Physician

Mihir Pradipkumar Raval, M.D. , M.P.H.

According to 2025 Medicare claims, Mihir Raval, M.D. , M.P.H. (NPI: 1962639427) practices internal medicine in the Albany-Schenectady-Troy, NY market, with the plurality of this provider's patient population coming from Albany, NY. This provider's primary affiliated billing organization is NEW YORK ONCOLOGY HEMATOLOGY, P.C. (NPI: 1609863448; TIN: 141799724) and primary practice location at 12208-3412.

Raval's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 555 traditional Medicare patients, billed 94,320 HCPCS/CPT codes, and received $2,313,547 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 2,777 prescription claims across 284 beneficiaries totaling $7,982,290 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 51 claims. Open Payments data shows 219 records totaling $257,809. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $50,114 to $2,313,547. Similarly, Part D prescription costs have moved sharply higher in recent years, from $17,721 to $7,982,290. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $12,841 to $4,057.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	195	694	$50,114
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	144	2,611	$74,988
2019	463	39,463	$754,932
2020	473	49,861	$1,064,319
2021	447	46,060	$962,851
2022	429	57,498	$1,193,927
2023	487	76,319	$1,379,991
2024	555	94,320	$2,313,547

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	131	579	$17,721
2016	41	129	$7,987
2017	39	108	$20,236
2018	58	141	$198,597
2019	130	619	$931,502
2020	139	1,103	$1,820,659
2021	157	1,340	$2,365,488
2022	215	2,114	$4,762,124
2023	243	2,272	$5,801,900
2024	284	2,777	$7,982,290

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	12	$78,758
2021	N/R	24	$960
2022	N/R	24	$994
2023	N/R	N/R	N/R
2024	N/R	51	$7,685

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	207	293	$61
80053	Blood test, comprehensive group of blood chemicals	365	909	$10
36415	Insertion of needle into vein for collection of blood sample	384	1,058	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	376	1,009	$8
83615	Lactate dehydrogenase (enzyme) level	258	556	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	101	2,856	$1,389,158
Revlimid	Lenalidomide	55	1,554	$931,043
Jakafi	Ruxolitinib Phosphate	69	2,050	$881,666
Calquence	Acalabrutinib Maleate	59	1,770	$803,715
Brukinsa	Zanubrutinib	46	1,380	$567,453

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	N	N/R	17	$3,670
J0895	Injection, deferoxamine mesylate, 500 mg	N	N/R	17	$3,645
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	17	$369

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	78	$108,039	GENZYME CORPORATION
Research Payments	Reported research-related payment or transfer-of-value amount.	141	$149,771	Genentech, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mihir Pradipkumar Raval, M.D. , M.P.H.?

Tedicare shows public-source Medicare data for Mihir Pradipkumar Raval, M.D. , M.P.H. (NPI 1962639427), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mihir Pradipkumar Raval, M.D. , M.P.H. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mihir Pradipkumar Raval, M.D. , M.P.H.?

Mihir Pradipkumar Raval, M.D. , M.P.H. is linked to NEW YORK ONCOLOGY HEMATOLOGY, P.C. (billing NPI 1609863448) in the available physician profile data.

Does Mihir Pradipkumar Raval, M.D. , M.P.H. have Open Payments data?

Mihir Pradipkumar Raval, M.D. , M.P.H. has 219 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.